Kedrion Biopharma

Nunzio Paolo oversees all processes, cleaning, equipment and computer system validations for a 700‑person plant producing life‑saving plasma‑derived therapies. With over a decade in biotech quality and compliance, he combines deep technical expertise with sceptical inquiry and innovative risk‑management techniques to ensure every batch of albumin, coagulation factors, and immunoglobulins meets the highest purity and safety standards before reaching patients worldwide.

Driving Validation with Scepticism and Statistical Rigour

Decade of hands-on experience in biotech validation means Paolo never takes ‘good enough’ for an answer. Leading 12 validation units and a four-unit calibration group at Kedrion’s 700-strong plasma plant, he applies statistical tools—Pareto charts, failure mode and effects analysis (FMEA) and Ishikawa diagrams—to remove hidden risks. That thorough approach keeps albumin and coagulation factors free of contaminants, safeguarding immunocompromised patients and bleeding disorder communities.

Under his leadership, cleaning validation programs for high-potency biologics have been refined to a near art form, balancing cost-efficiency with uncompromising product safety. His approach blends deep statistical insight with practical floor experience, turning theoretical compliance frameworks into tangible community health protections.

Cultivating Cross-Functional Synergy

Validation doesn’t happen in a vacuum. By constructively challenging engineering assumptions—such as asking, “Are we sure about that valve gasket?”—and closely collaborating with CMC and Regulatory Affairs, Paolo accelerates qualification timelines without compromising compliance. The same level of rigour applies to outsourced activities. From tracking vendor KPIs and conducting detailed document reviews to performing unannounced calibration checks, every measure ensures each batch meets Kedrion’s stringent standards and reaches clinics on time.

Through joint planning sessions, integrated validation roadmaps and hands-on troubleshooting workshops, he’s helped tear down silos and build a factory floor culture where QA, maintenance and regulatory teams operate like synchronised gears. The result? More predictable timelines, fewer deviations and faster delivery of vital medicines to patients.

Turning Regulatory Rigour into Patient Hope

Paolo stays two steps ahead in the regulatory landscape, interpreting complex frameworks—such as European Union legislation, Title 21 of the Code of Federal Regulations (21 CFR) and International Council for Harmonisation (ICH) guidelines—with the precision of reading fine print in a contract. As Kedrion’s designated liaison during global regulatory inspections, he ensures doors remain open and supply chains stay uninterrupted.

But his impact extends far beyond current products. Through his technical writing contributions to Chemistry, Manufacturing and Controls (CMC) sections in Investigational New Drug (IND) and Biologics License Application (BLA) submissions, Paolo helps lay the groundwork for the next generation of immunoglobulin therapies, offering hope to underserved patient populations worldwide.

The future of biotechnology is being written in validation protocols, and Paolo is holding the pen. His work enables Kedrion to deliver advanced plasma-derived therapies to emerging markets, where demand is high but access remains limited. With every submission, Paolo’s precision and clarity win more than just regulatory approval; they win time. And for patients living with chronic conditions, time is everything.